BE2015C007I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C007I2
BE2015C007I2 BE2015C007C BE2015C007C BE2015C007I2 BE 2015C007 I2 BE2015C007 I2 BE 2015C007I2 BE 2015C007 C BE2015C007 C BE 2015C007C BE 2015C007 C BE2015C007 C BE 2015C007C BE 2015C007 I2 BE2015C007 I2 BE 2015C007I2
Authority
BE
Belgium
Application number
BE2015C007C
Other languages
French (fr)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C007(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BE2015C007I2 publication Critical patent/BE2015C007I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
BE2015C007C 2003-06-12 2015-02-02 BE2015C007I2 (un)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12
PCT/US2004/015595 WO2005000892A2 (en) 2003-06-12 2004-06-10 Glp-1 analog fusion plroteins

Publications (1)

Publication Number Publication Date
BE2015C007I2 true BE2015C007I2 (un) 2023-08-09

Family

ID=33551775

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C007C BE2015C007I2 (un) 2003-06-12 2015-02-02

Country Status (29)

Country Link
US (2) US7452966B2 (un)
EP (2) EP1641823B1 (un)
JP (1) JP4629047B2 (un)
KR (1) KR100758755B1 (un)
CN (2) CN101974090B (un)
AR (1) AR044776A1 (un)
AT (1) ATE525395T1 (un)
AU (1) AU2004251145C1 (un)
BE (1) BE2015C007I2 (un)
BR (1) BRPI0411132B8 (un)
CA (1) CA2528591C (un)
CY (2) CY1111991T1 (un)
DK (1) DK1641823T3 (un)
EA (1) EA008831B1 (un)
ES (1) ES2371072T3 (un)
FR (1) FR15C0010I2 (un)
HK (1) HK1149566A1 (un)
HR (1) HRP20110714T1 (un)
HU (1) HUS1500024I1 (un)
IL (1) IL171926A (un)
LT (1) LTC1641823I2 (un)
MX (1) MXPA05013565A (un)
NZ (1) NZ543292A (un)
PL (1) PL1641823T3 (un)
PT (1) PT1641823E (un)
SI (1) SI1641823T1 (un)
TW (1) TW200507870A (un)
UA (1) UA87458C2 (un)
WO (1) WO2005000892A2 (un)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1443961B1 (en) * 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
SI1641823T1 (sl) * 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
AU2005319432A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company GLP-1 analog fusion protein formulations
WO2006124529A1 (en) * 2005-05-13 2006-11-23 Eli Lilly And Company Glp-1 pegylated compounds
EP1920061A4 (en) * 2005-07-27 2009-05-13 Wang Qinghua GLP / 1 / EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR THE TREATMENT OF DIABETES
CA2658678A1 (en) 2005-08-06 2007-02-15 Gerald J. Prud'homme Composition and method for prevention and treatment of type i diabetes
DK1767545T3 (da) * 2005-09-22 2010-03-15 Biocompatibles Uk Ltd GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
AU2006321743A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2009514900A (ja) 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
ES2507098T3 (es) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
WO2008028117A2 (en) * 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
CN103230598A (zh) * 2006-09-06 2013-08-07 费斯生物制药公司 融合肽治疗组合物
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2124974B1 (en) * 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
EP2526962B1 (en) 2007-02-12 2019-08-14 CSL Behring GmbH Therapeutic application of Kazal-type serine protease inhibitors
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN101951940A (zh) * 2007-03-15 2011-01-19 比奥根艾迪克Ma公司 自身免疫病的治疗
RU2539829C2 (ru) * 2007-06-19 2015-01-27 ГЛИТЕК,ИНК.,Япония Пептид glp-1 с присоединенной олигосахаридной цепью
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP5771005B2 (ja) * 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN101983066B (zh) * 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL2300035T3 (pl) * 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
US8546327B2 (en) 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
ES2654336T3 (es) 2008-06-24 2018-02-13 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
CA2764835A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2011043530A1 (ko) * 2009-10-09 2011-04-14 (주)알테오젠 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2683397B1 (en) 2011-03-09 2017-08-09 CSL Behring GmbH Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
CA2841185C (en) 2011-07-22 2021-05-25 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
AU2013315499B2 (en) * 2012-09-12 2018-08-09 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
CN104870019A (zh) 2012-11-27 2015-08-26 阿特根公司 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物
KR102262882B1 (ko) 2012-11-27 2021-06-10 바이오마린 파머수티컬 인크. 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
BR112015020885A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp polipeptídeos de ligação hiperglicosilados
RU2678134C2 (ru) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
ES2897746T3 (es) 2013-06-28 2022-03-02 Csl Behring Gmbh Terapia combinada con un inhibidor del Factor XII y un inhibidor de C1
CN103408669B (zh) 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
SG10202107752PA (en) * 2014-03-31 2021-09-29 Hanmi Pharmaceutical Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PL3157548T3 (pl) 2014-06-18 2022-01-17 Csl Behring Gmbh Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
SG10202010158TA (en) 2014-07-21 2020-11-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN104293834B (zh) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
RU2729011C2 (ru) 2014-12-23 2020-08-03 Ново Нордиск А/С Производные fgf21 и их применения
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
RU2017145002A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Способы получения модифицированного фактора фон виллебранда
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR20170049320A (ko) 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
ES2881701T3 (es) 2016-01-07 2021-11-30 CSL Behring Lengnau AG Factor de von Willebrand mutado
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017173494A1 (en) 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CN110121355B (zh) 2016-11-10 2023-09-12 株式会社柳韩洋行 用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
EP3351262A1 (en) 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JP7191850B2 (ja) 2017-04-21 2022-12-19 ユーハン・コーポレイション デュアル機能タンパク質およびその誘導体を生産するための方法
PL3630164T3 (pl) 2017-06-01 2024-01-29 Eli Lilly And Company Dulaglutyd do leczenia przewlekłej choroby nerek
KR20200018690A (ko) 2017-06-22 2020-02-19 체에스엘 베링 렝나우 아게 절단된 vwf에 의한 fviii 면역원성의 조절
EP3684793A1 (en) 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof
EP3713593A2 (en) 2017-11-21 2020-09-30 Eli Lilly and Company Methods of using and compositions containing dulaglutide
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
WO2019125003A1 (ko) * 2017-12-22 2019-06-27 케이비바이오메드 주식회사 경구용 유전자 전달체 및 이의 용도
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
EP3823659A4 (en) 2018-07-19 2022-06-22 D&D Pharmatech Inc. PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE
CN110878127B (zh) 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 长效重组GLP1-Fc-CD47蛋白及其制备和用途
CN111234000B (zh) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 艾塞纳肽类似物
CN111269312B (zh) * 2018-12-04 2023-05-09 鲁南制药集团股份有限公司 一种异源融合蛋白质
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
EP3934679A1 (en) 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
US20220143187A1 (en) 2019-03-15 2022-05-12 Eli Lilly And Company Preserved formulations
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
JP2022533365A (ja) 2019-05-17 2022-07-22 ウニベルシテート チューリッヒ 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン
CN114072420A (zh) 2019-07-04 2022-02-18 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CA3190399A1 (en) 2020-08-24 2022-03-03 James M. Wilson Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
EP4247416A1 (en) 2020-11-20 2023-09-27 CSL Behring GmbH Method for treating antibody-mediated rejection
CN114685644A (zh) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
AU2022214388A1 (en) 2021-02-01 2023-07-27 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
CA3217518A1 (en) 2021-05-07 2022-11-10 Rebecca Butcher Expression system for producing a recombinant haptoglobin (hp) beta chain
WO2023280133A1 (zh) 2021-07-06 2023-01-12 苏州康宁杰瑞生物科技有限公司 融合蛋白及其应用
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
DE68927344T2 (de) 1989-04-28 1997-02-20 Rhein Biotech Proz & Prod Gmbh Hefezellen der Gattung-Schwanniomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
AU669960B2 (en) 1992-11-13 1996-06-27 Immunex Corporation Novel cytokine designated elk ligand
CA2196200A1 (en) * 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
WO2000007617A1 (en) 1998-07-31 2000-02-17 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
EA008837B1 (ru) 2000-06-16 2007-08-31 Эли Лилли Энд Компани Аналоги глюкагоноподобного пептида и их применение
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
SI1641823T1 (sl) * 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1

Also Published As

Publication number Publication date
ATE525395T1 (de) 2011-10-15
DK1641823T3 (da) 2011-12-12
IL171926A0 (en) 2006-04-10
UA87458C2 (ru) 2009-07-27
PT1641823E (pt) 2011-11-08
CA2528591C (en) 2013-01-08
KR100758755B1 (ko) 2007-09-14
LTC1641823I2 (lt) 2016-12-12
CN1802386A (zh) 2006-07-12
US20090074769A1 (en) 2009-03-19
WO2005000892A2 (en) 2005-01-06
AU2004251145B2 (en) 2010-09-09
CN1802386B (zh) 2010-12-15
AU2004251145A1 (en) 2005-01-06
SI1641823T1 (sl) 2011-12-30
CY2015002I1 (el) 2015-11-04
HUS1500024I1 (hu) 2017-04-28
TW200507870A (en) 2005-03-01
PL1641823T3 (pl) 2012-02-29
JP4629047B2 (ja) 2011-02-09
MXPA05013565A (es) 2006-03-09
CY1111991T1 (el) 2015-11-04
FR15C0010I2 (fr) 2015-07-24
HK1149566A1 (en) 2011-10-07
US7452966B2 (en) 2008-11-18
CN101974090A (zh) 2011-02-16
HRP20110714T1 (hr) 2011-11-30
ES2371072T3 (es) 2011-12-27
JP2007536902A (ja) 2007-12-20
FR15C0010I1 (un) 2015-03-13
EA008831B1 (ru) 2007-08-31
BRPI0411132B1 (pt) 2016-12-13
EP1641823A2 (en) 2006-04-05
IL171926A (en) 2010-12-30
CY2015002I2 (el) 2017-04-05
US20070036806A1 (en) 2007-02-15
NZ543292A (en) 2008-04-30
WO2005000892A3 (en) 2005-03-03
EA200600015A1 (ru) 2006-06-30
US8273854B2 (en) 2012-09-25
CA2528591A1 (en) 2005-01-06
BRPI0411132A (pt) 2006-07-18
CN101974090B (zh) 2015-06-17
BRPI0411132B8 (pt) 2021-05-25
KR20060022262A (ko) 2006-03-09
EP2368909A1 (en) 2011-09-28
EP1641823B1 (en) 2011-09-21
AR044776A1 (es) 2005-10-05
AU2004251145C1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
BE2015C007I2 (un)
BE2014C055I2 (un)
BE2014C027I2 (un)
BE2014C003I2 (un)
BE2013C075I2 (un)
BE2013C070I2 (un)
BE2013C067I2 (un)
BE2013C038I2 (un)
BE2013C036I2 (un)
BE2011C030I2 (un)
JP2003314704A5 (un)
JP2003240894A5 (un)
BE2015C005I2 (un)
JP2003319467A5 (un)
BE2012C053I2 (un)
JP2004096719A5 (un)
JP2004142459A5 (un)
DE502004007013D1 (un)
JP2004066812A5 (un)
JP2004208683A5 (un)
JP2004067074A5 (un)
JP2003341249A5 (un)
JP2004053012A5 (un)
BE2015C024I2 (un)
AU2003210772A1 (un)